The court ordered the molecular diagnostic company to stop offering the Fetalis test it started offering in Germany this summer, which is based on Ariosa's technology.
Roche said it will offer the microarray-based Harmony IVD kit and Ariosa Cell-Free DNA System (AcfS) software to laboratories outside the US.
Last week, the G-BA, a committee that decides about reimbursable medical services in Germany, said it will start a methods evaluation of noninvasive prenatal testing.
United Healthcare, Aetna, Cigna, and Anthem now cover the Harmony test, which predicts fetal risk for trisomies 21, 18, and 13.
St. George's University Hospitals NHS Foundation Trust, which has been offering NIPT since last year, plans to double its capacity by the third quarter.
The company has sued three companies in the UK and two in Poland alleging they infringed on the firm's non-invasive prenatal testing patents.
Several new laboratories started to offer NIPT locally in 2015, and some providers have been shifting to less-expensive non-NGS platforms.
The firm's clinical data showed comparable performance between NIPT by microarray and NGS, but the switch to arrays has helped speed turnaround times.
Prices in Germany for noninvasive prenatal testing have plummeted over the last year, driven by competition and process improvements.
Sonic will make the blood-based Harmony test, which assesses the risk of a fetus having trisomy 21, available in Australia and the UK.
A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.
Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.
Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.
In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.